SlideShare uma empresa Scribd logo
1 de 46
Baixar para ler offline
{
Banting, Best,
Collip y MacLeod
1921
Islotina
Mc-Collip
Leonard
Thompson
11 enero 1922
1936 Hagedorn
1946 NPH
Scott y Fisher
zinc
Entrada glucosa
Inhibe
producción
hepática glucosa
Inhibe lipólisis,
proteólisis
Promueve
síntesis proteica
Conversión del
exceso glucosa a
grasa
Insulinas porcinas y
bovinas
Insulina humana
Análogos de insulina
Insulina inhalada
RAZON?
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda
Insulinas
Prandiales
Basales
Precombinadas
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda
Insulina rápida humana
Velocidad de absorción baja
Inicia 15 a 60 mins tras inyección
Pico 2 a 4 horas. Acción máx.: 5-8 hrs
I. Prandiales: Lispro
L
p
Inicia 15
mins
EM: 60-90
mins
Actua 4-5
hrs
Flexible
I. Prandiales: Aspart
A
Glulisina
L
G
INSULINA INHALADA:
1. Insulina de acción rápida
2. No pctes con asma, broncoespasmos,
EPOC o cualquier otra enfermedad
pulmonar crónica
•No en CAD
Insulinas basales: NPH
Inicia 2.5-
3 hrs
Pico 5-7
hrs
Duración
13-16 hrs
Reducción
basal
I. Basales: Detemir
I. Basales: Glargina
A A
G
• Degludec
• U300 glargina (Toujeo)
• Peglispro
INSULINAS MODERNAS
http://www.medscape.com/viewarticle/
Insulinas precombinadas
NPL 75/25
NPA 70/30
Insulina
70/30
Problemas
autocombinación
Ancianos
Trastorno
motricidad fina
y/o visuales
No fácil ajuste
Inadecuadas
DM 1
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda
Objetivos de insulinoterapia
Prevenir y retrasar complicaciones
micro y macrovasculares
Evitar CAD
Detener catabolia y recuperar masa
magra
Reducir infecciones frecuentes
Reducir morbimortalidad materno-
fetal
ADA-EASD Position Statement Update:
Management of Hyperglycemia in T2DM, 2015
larga (Detemir)
Ultra-rápida (Lispro, Aspártica, Glulisina)
Hours
Larga (Glargina)
0 2 4 6 8 10 12 14 16 18 20 22 24
Rápida (Regular)
Horas después injección
Niveldeinsulina
(Degludec)
TERAPIA ANTI-HIPERGLICEMICA
NPH
Healthy eating, weight control, increased physical activity & diabetes education
Metformin
high
low risk
neutral/loss
GI / lactic acidosis
low
If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
high
low risk
gain
edema, HF, fxs
low
Thiazolidine-
dione
intermediate
low risk
neutral
rare
high
DPP-4
inhibitor
highest
high risk
gain
hypoglycemia
variable
Insulin (basal)
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Basal Insulin +
Sulfonylurea
+
TZD
DPP-4-i
GLP-1-RA
Insulin§
or
or
or
or
Thiazolidine-
dione
+
SU
DPP-4-i
GLP-1-RA
Insulin§
TZD
DPP-4-ior
or
or GLP-1-RA
high
low risk
loss
GI
high
GLP-1 receptor
agonist
Sulfonylurea
high
moderate risk
gain
hypoglycemia
low
SGLT2
inhibitor
intermediate
low risk
loss
GU, dehydration
high
SU
TZD
Insulin§
GLP-1 receptor
agonist
+
SGLT-2
Inhibitor
+
SU
TZD
Insulin§
Metformin
+
Metformin
+
or
or
or
or
SGLT2-i
or
or
or
SGLT2-i
Mono-
therapy
Efficacy*
Hypo risk
Weight
Side effects
Costs
Dual
therapy†
Efficacy*
Hypo risk
Weight
Side effects
Costs
Triple
therapy
or
or
DPP-4
Inhibitor
+
SU
TZD
Insulin§
SGLT2-i
or
or
or
SGLT2-i
or
DPP-4-i
If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add
basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i:
Metformin
+
Combination
injectable
therapy‡
GLP-1-RAMealtime Insulin
Insulin (basal)
+
Terapia antihiperglicémica:
recomendaciones generales Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
Healthy eating, weight control, increased physical activity & diabetes education
Metformin
high
low risk
neutral/loss
GI / lactic acidosis
low
If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
high
low risk
gain
edema, HF, fxs
low
Thiazolidine-
dione
intermediate
low risk
neutral
rare
high
DPP-4
inhibitor
highest
high risk
gain
hypoglycemia
variable
Insulin (basal)
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Basal Insulin +
Sulfonylurea
+
TZD
DPP-4-i
GLP-1-RA
Insulin§
or
or
or
or
Thiazolidine-
dione
+
SU
DPP-4-i
GLP-1-RA
Insulin§
TZD
DPP-4-ior
or
or GLP-1-RA
high
low risk
loss
GI
high
GLP-1 receptor
agonist
Sulfonylurea
high
moderate risk
gain
hypoglycemia
low
SGLT2
inhibitor
intermediate
low risk
loss
GU, dehydration
high
SU
TZD
Insulin§
GLP-1 receptor
agonist
+
SGLT-2
Inhibitor
+
SU
TZD
Insulin§
Metformin
+
Metformin
+
or
or
or
or
SGLT2-i
or
or
or
SGLT2-i
Mono-
therapy
Efficacy*
Hypo risk
Weight
Side effects
Costs
Dual
therapy†
Efficacy*
Hypo risk
Weight
Side effects
Costs
Triple
therapy
or
or
DPP-4
Inhibitor
+
SU
TZD
Insulin§
SGLT2-i
or
or
or
SGLT2-i
or
DPP-4-i
If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add
basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i:
Metformin
+
Combination
injectable
therapy‡
GLP-1-RAMealtime Insulin
Insulin (basal)
+
Terapia antihiperglicémica:
Recomendaciones generales Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
Healthy eating, weight control, increased physical activity & diabetes education
Metformin
high
low risk
neutral/loss
GI / lactic acidosis
low
If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
high
low risk
gain
edema, HF, fxs
low
Thiazolidine-
dione
intermediate
low risk
neutral
rare
high
DPP-4
inhibitor
highest
high risk
gain
hypoglycemia
variable
Insulin (basal)
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Basal Insulin +
Sulfonylurea
+
TZD
DPP-4-i
GLP-1-RA
Insulin§
or
or
or
or
Thiazolidine-
dione
+
SU
DPP-4-i
GLP-1-RA
Insulin§
TZD
DPP-4-ior
or
or GLP-1-RA
high
low risk
loss
GI
high
GLP-1 receptor
agonist
Sulfonylurea
high
moderate risk
gain
hypoglycemia
low
SGLT2
inhibitor
intermediate
low risk
loss
GU, dehydration
high
SU
TZD
Insulin§
GLP-1 receptor
agonist
+
SGLT-2
Inhibitor
+
SU
TZD
Insulin§
Metformin
+
Metformin
+
or
or
or
or
SGLT2-i
or
or
or
SGLT2-i
Mono-
therapy
Efficacy*
Hypo risk
Weight
Side effects
Costs
Dual
therapy†
Efficacy*
Hypo risk
Weight
Side effects
Costs
Triple
therapy
or
or
DPP-4
Inhibitor
+
SU
TZD
Insulin§
SGLT2-i
or
or
or
SGLT2-i
or
DPP-4-i
If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add
basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i:
Metformin
+
Combination
injectable
therapy‡
GLP-1-RAMealtime Insulin
Insulin (basal)
+
Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
Healthy eating, weight control, increased physical activity & diabetes education
Metformin
high
low risk
neutral/loss
GI / lactic acidosis
low
If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
high
low risk
gain
edema, HF, fxs
low
Thiazolidine-
dione
intermediate
low risk
neutral
rare
high
DPP-4
inhibitor
highest
high risk
gain
hypoglycemia
variable
Insulin (basal)
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Basal Insulin +
Sulfonylurea
+
TZD
DPP-4-i
GLP-1-RA
Insulin§
or
or
or
or
Thiazolidine-
dione
+
SU
DPP-4-i
GLP-1-RA
Insulin§
TZD
DPP-4-ior
or
or GLP-1-RA
high
low risk
loss
GI
high
GLP-1 receptor
agonist
Sulfonylurea
high
moderate risk
gain
hypoglycemia
low
SGLT2
inhibitor
intermediate
low risk
loss
GU, dehydration
high
SU
TZD
Insulin§
GLP-1 receptor
agonist
+
SGLT-2
Inhibitor
+
SU
TZD
Insulin§
Metformin
+
Metformin
+
or
or
or
or
SGLT2-i
or
or
or
SGLT2-i
Mono-
therapy
Efficacy*
Hypo risk
Weight
Side effects
Costs
Dual
therapy†
Efficacy*
Hypo risk
Weight
Side effects
Costs
Triple
therapy
or
or
DPP-4
Inhibitor
+
SU
TZD
Insulin§
SGLT2-i
or
or
or
SGLT2-i
or
DPP-4-i
If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add
basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i:
Metformin
+
Combination
injectable
therapy‡
GLP-1-RAMealtime Insulin
Insulin (basal)
+
Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
Healthy eating, weight control, increased physical activity & diabetes education
Metformin
high
low risk
neutral/loss
GI / lactic acidosis
low
If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
high
low risk
gain
edema, HF, fxs
low
Thiazolidine-
dione
intermediate
low risk
neutral
rare
high
DPP-4
inhibitor
highest
high risk
gain
hypoglycemia
variable
Insulin (basal)
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Metformin
+
Basal Insulin +
Sulfonylurea
+
TZD
DPP-4-i
GLP-1-RA
Insulin§
or
or
or
or
Thiazolidine-
dione
+
SU
DPP-4-i
GLP-1-RA
Insulin§
TZD
DPP-4-ior
or
or GLP-1-RA
high
low risk
loss
GI
high
GLP-1 receptor
agonist
Sulfonylurea
high
moderate risk
gain
hypoglycemia
low
SGLT2
inhibitor
intermediate
low risk
loss
GU, dehydration
high
SU
TZD
Insulin§
GLP-1 receptor
agonist
+
SGLT-2
Inhibitor
+
SU
TZD
Insulin§
Metformin
+
Metformin
+
or
or
or
or
SGLT2-i
or
or
or
SGLT2-i
Mono-
therapy
Efficacy*
Hypo risk
Weight
Side effects
Costs
Dual
therapy†
Efficacy*
Hypo risk
Weight
Side effects
Costs
Triple
therapy
or
or
DPP-4
Inhibitor
+
SU
TZD
Insulin§
SGLT2-i
or
or
or
SGLT2-i
or
DPP-4-i
If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote
any specific preference - choice dependent on a variety of patient- & disease-specific factors):
If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add
basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i:
Metformin
+
Combination
injectable
therapy‡
GLP-1-RAMealtime Insulin
Insulin (basal)
+
Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
HbA1c
≥9%
Intolerancia o
contraindicación
metformina
Hiperglicemia
incontrolada
(cuadros catabólicos,
Gp ≥300-350 mg/dl,
HbA1c ≥10-12%)
A QUIEN??
Inicio DM 1 y DM2 con
síntomas
Cuadros agudos,
hospitalización
Diabetes gestacional sin
control y pregestacional
Insuficiencia renal y hepática
Falla terapéutica ADO
CON EL TX DE INSULINA EN RECIEN DX SE HA
DEMOSTRADO UN AUMENTO DE LA SECRESION DE LA
MISMA TANTO 1ERA COMO 2DA FASE
ORIGIN
A DOSIS 0.1 A 0.15 U DE ANALOGOS REDUCIENDO 30-35 %
DE LA PROGRESION DE DIABETES
• Edad/expectativa de vida
• Comorbilidades
• Duración de la diabetes
• Hipoglicemias
• Consideraciones individuales
• Enf. Cardiovasculares/ complicaciones
microvasculares avanzadas
more
stringent
less
stringent
Patient attitude and
expected treatment efforts highly motivated, adherent,
excellent self-care capacities
less motivated, non-adherent,
poor self-care capacities
Risks potentially associated
with hypoglycemia and
other drug adverse effects
low high
Disease duration
newly diagnosed long-standing
Life expectancy
long short
Important comorbidities
absent severefew / mild
Established vascular
complications absent severefew / mild
Readily available limited
Usually not
modifiable
Potentially
modifiable
HbA1c
7%
PATIENT / DISEASE FEATURES
Approach to the management
of hyperglycemia
Resources and support
system
Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
DOSIS DE INSULINA
Add ≥2 rapid insulin* injections
before meals ('basal-bolus’†
)
Change to
premixed insulin* twice daily
Add 1 rapid insulin* injections
before largest meal
• Start: Divide current basal dose into 2/3 AM,
1/3 PM or 1/2 AM, 1/2 PM.
• Adjust: é dose by 1-2 U or 10-15% once-
twice weekly until SMBG target reached.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
• Start: 10U/day or 0.1-0.2 U/kg/day
• Adjust: 10-15% or 2-4 U once-twice weekly to
reach FBG target.
• For hypo: Determine & address cause;
ê dose by 4 units or 10-20%.
Basal Insulin
(usually with metformin +/-
other non-insulin agent)
If not
controlled after
FBG target is reached
(or if dose > 0.5 U/kg/day),
treat PPG excursions with
meal-time insulin.
(Consider initial
GLP-1-RA
trial.)
If not
controlled,
consider basal-
bolus.
If not
controlled,
consider basal-
bolus.
• Start: 4U, 0.1 U/kg, or 10% basal dose. If
A1c<8%, consider ê basal by same amount.
• Adjust: é dose by 1-2 U or 10-15% once-
twice weekly until SMBG target reached.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
• Start: 4U, 0.1 U/kg, or 10% basal dose/meal.‡
If
A1c<8%, consider ê basal by same amount.
• Adjust: é dose by 1-2 U or 10-15% once-twice
weekly to achieve SMBG target.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
Enfoque
para inicio
y ajuste de
tx
insulínico
Dm 2
Diabetes Care 2015;38:140-149;
Diabetologia 2015;58:429-442
Add ≥2 rapid insulin* injections
before meals ('basal-bolus’†
)
Change to
premixed insulin* twice daily
Add 1 rapid insulin* injections
before largest meal
• Start: Divide current basal dose into 2/3 AM,
1/3 PM or 1/2 AM, 1/2 PM.
• Adjust: é dose by 1-2 U or 10-15% once-
twice weekly until SMBG target reached.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
• Start: 10U/day or 0.1-0.2 U/kg/day
• Adjust: 10-15% or 2-4 U once-twice weekly to
reach FBG target.
• For hypo: Determine & address cause;
ê dose by 4 units or 10-20%.
Basal Insulin
(usually with metformin +/-
other non-insulin agent)
If not
controlled after
FBG target is reached
(or if dose > 0.5 U/kg/day),
treat PPG excursions with
meal-time insulin.
(Consider initial
GLP-1-RA
trial.)
low
mod.
high
more flexible less flexible
Complexity
#
Injections
Flexibility
1
2
3+
If not
controlled,
consider basal-
bolus.
If not
controlled,
consider basal-
bolus.
• Start: 4U, 0.1 U/kg, or 10% basal dose. If
A1c<8%, consider ê basal by same amount.
• Adjust: é dose by 1-2 U or 10-15% once-
twice weekly until SMBG target reached.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
• Start: 4U, 0.1 U/kg, or 10% basal dose/meal.‡
If
A1c<8%, consider ê basal by same amount.
• Adjust: é dose by 1-2 U or 10-15% once-twice
weekly to achieve SMBG target.
• For hypo: Determine and address cause;
ê corresponding dose by 2-4 U or 10-20%.
Enfoque
para inicio
y ajuste de
tx
insulinico
Dm2
Diabetes Care 2015;38:140-149;
Diabetologia 2015;58:429-442
0.2 a 0.5 U/ kg: 50% basal (2/3 y 1/3)
50% bolus
Conteo CBH: 1 U <> 15 g CBH
Automonitoreo
DM 1
Síntomas de
hiperglicemia
Contraindicación
ADO
HbA1c >9 %
Cuadros agudos
GA >250 mg/dl y
GPP > 350 mg/dl
Embarazo
DM 2
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda
{
CenaAlmuerzoDesayuno
5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am
3am 4am
Horarios y tiempos de
comida
{ CenaAlmuerzoDesayuno
5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am
3am 4am
Horarios y tiempos de
comida
{
CenaAlmuerzoDesayuno
5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am
3am 4am
Horarios y tiempos de
comida
{
CenaAlmuerzoDesayuno
5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am
3am 4am
Horarios y tiempos de
comida
{
CenaAlmuerzoDesayuno
5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am
3am 4am
Horarios y tiempos de
comida
http://es.paperblog.com/donde-se-aplica-la-insulina-2711226/
Hipoglicemia
Ganancia de
peso
Alergia
Lipodistrofia Edema Presbiopenia
EFECTOS ADVERSOS
Conclusión
Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda

Mais conteúdo relacionado

Mais procurados

Mais procurados (20)

Insulinoterapia
InsulinoterapiaInsulinoterapia
Insulinoterapia
 
Insulinas e insulinización
Insulinas e insulinizaciónInsulinas e insulinización
Insulinas e insulinización
 
Rol de la enfermera en insulinoterapia
Rol de la enfermera en insulinoterapiaRol de la enfermera en insulinoterapia
Rol de la enfermera en insulinoterapia
 
Tallerdeinsulina
TallerdeinsulinaTallerdeinsulina
Tallerdeinsulina
 
Taller de manejo de insulinas
Taller de manejo de insulinasTaller de manejo de insulinas
Taller de manejo de insulinas
 
Insulinoterapia
InsulinoterapiaInsulinoterapia
Insulinoterapia
 
36. insulinoterapia
36. insulinoterapia36. insulinoterapia
36. insulinoterapia
 
(2012-11-08)Diabetes mellitus e insulinas (ppt)
(2012-11-08)Diabetes mellitus e insulinas (ppt)(2012-11-08)Diabetes mellitus e insulinas (ppt)
(2012-11-08)Diabetes mellitus e insulinas (ppt)
 
Diabetes and insulin dr jayesh vaghela
Diabetes and insulin dr jayesh vaghelaDiabetes and insulin dr jayesh vaghela
Diabetes and insulin dr jayesh vaghela
 
Insulinas
InsulinasInsulinas
Insulinas
 
Taller de insulinas
Taller de insulinasTaller de insulinas
Taller de insulinas
 
Nuevos fármacos antidiabéticos (2)
Nuevos fármacos antidiabéticos (2)Nuevos fármacos antidiabéticos (2)
Nuevos fármacos antidiabéticos (2)
 
Inhibidores de SGLT2
Inhibidores de SGLT2Inhibidores de SGLT2
Inhibidores de SGLT2
 
Insulinoterapia
Insulinoterapia Insulinoterapia
Insulinoterapia
 
Diapositivas de insulina sy
Diapositivas de insulina syDiapositivas de insulina sy
Diapositivas de insulina sy
 
Uso de insulina en la práctica médica
Uso de insulina en la práctica médicaUso de insulina en la práctica médica
Uso de insulina en la práctica médica
 
Tratamiento farmacologico dm2
Tratamiento farmacologico dm2Tratamiento farmacologico dm2
Tratamiento farmacologico dm2
 
Insulina
InsulinaInsulina
Insulina
 
Insulina para principiantes y demás
Insulina para principiantes y demásInsulina para principiantes y demás
Insulina para principiantes y demás
 
Taller de insulina
Taller de insulinaTaller de insulina
Taller de insulina
 

Destaque

Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?mataharitimoer MT
 
Desarrolla tus Áreas de mayor productividad
Desarrolla tus Áreas de mayor productividadDesarrolla tus Áreas de mayor productividad
Desarrolla tus Áreas de mayor productividadRoberto Miramontes
 
Aprender a Ser (Know To BE) en la RED
Aprender a Ser (Know To BE) en la REDAprender a Ser (Know To BE) en la RED
Aprender a Ser (Know To BE) en la REDerubio
 
Desarrolla Tus áreas de Mayor Productividad .pdf
Desarrolla Tus áreas de Mayor Productividad .pdfDesarrolla Tus áreas de Mayor Productividad .pdf
Desarrolla Tus áreas de Mayor Productividad .pdfRoberto Miramontes
 
Estrategias de integracion interhemisferica
Estrategias de integracion interhemisfericaEstrategias de integracion interhemisferica
Estrategias de integracion interhemisfericaDarwin Zamudio
 
Habilidades para la vida
Habilidades para la vidaHabilidades para la vida
Habilidades para la vidaPlusia
 
El Lider del Futuro La Vision de una Nueva Era
El Lider del Futuro  La Vision de una Nueva EraEl Lider del Futuro  La Vision de una Nueva Era
El Lider del Futuro La Vision de una Nueva EraDr. Orville M. Disdier
 
Presentación modelo de benziger noviembre 2015
Presentación modelo de benziger noviembre 2015Presentación modelo de benziger noviembre 2015
Presentación modelo de benziger noviembre 2015czbillig
 
Insulinoterapia
InsulinoterapiaInsulinoterapia
InsulinoterapiaBrianHall
 
Habilidades para la vida una mirada desde la fpi
Habilidades para la vida una mirada desde la fpiHabilidades para la vida una mirada desde la fpi
Habilidades para la vida una mirada desde la fpizuleyma_garces
 
Habilidades para la vida
Habilidades para la vidaHabilidades para la vida
Habilidades para la vidaMaylet Gonzalez
 

Destaque (18)

Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?Insulin Initiation : When We should Start with Basal Insulin?
Insulin Initiation : When We should Start with Basal Insulin?
 
Desarrolla tus Áreas de mayor productividad
Desarrolla tus Áreas de mayor productividadDesarrolla tus Áreas de mayor productividad
Desarrolla tus Áreas de mayor productividad
 
Aprender a Ser (Know To BE) en la RED
Aprender a Ser (Know To BE) en la REDAprender a Ser (Know To BE) en la RED
Aprender a Ser (Know To BE) en la RED
 
Grundtvig project
Grundtvig projectGrundtvig project
Grundtvig project
 
Desarrolla Tus áreas de Mayor Productividad .pdf
Desarrolla Tus áreas de Mayor Productividad .pdfDesarrolla Tus áreas de Mayor Productividad .pdf
Desarrolla Tus áreas de Mayor Productividad .pdf
 
Insulinoterapia
InsulinoterapiaInsulinoterapia
Insulinoterapia
 
Pmi Educacion
Pmi EducacionPmi Educacion
Pmi Educacion
 
Estrategias de integracion interhemisferica
Estrategias de integracion interhemisfericaEstrategias de integracion interhemisferica
Estrategias de integracion interhemisferica
 
Habilidades para la vida
Habilidades para la vidaHabilidades para la vida
Habilidades para la vida
 
El Lider del Futuro La Vision de una Nueva Era
El Lider del Futuro  La Vision de una Nueva EraEl Lider del Futuro  La Vision de una Nueva Era
El Lider del Futuro La Vision de una Nueva Era
 
Presentación modelo de benziger noviembre 2015
Presentación modelo de benziger noviembre 2015Presentación modelo de benziger noviembre 2015
Presentación modelo de benziger noviembre 2015
 
Dominancia cerebral
Dominancia cerebralDominancia cerebral
Dominancia cerebral
 
Insulinoterapia
InsulinoterapiaInsulinoterapia
Insulinoterapia
 
Habilidades para la Vida
Habilidades para la VidaHabilidades para la Vida
Habilidades para la Vida
 
Habilidades para la vida una mirada desde la fpi
Habilidades para la vida una mirada desde la fpiHabilidades para la vida una mirada desde la fpi
Habilidades para la vida una mirada desde la fpi
 
Habilidades para la vida
Habilidades para la vidaHabilidades para la vida
Habilidades para la vida
 
Dominancia cerebral
Dominancia cerebralDominancia cerebral
Dominancia cerebral
 
HABILIDADES PARA LA VIDA
HABILIDADES PARA LA VIDAHABILIDADES PARA LA VIDA
HABILIDADES PARA LA VIDA
 

Semelhante a Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda

Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise -  khaled el hadidyUeda2016 symposium -managing t2 dm with no compromise -  khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidyueda2015
 
Diabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptxDiabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptxDr.Sajid Hasan
 
ueda2013 t2-dm achieving target challenges_d.lobna
ueda2013 t2-dm achieving target challenges_d.lobnaueda2013 t2-dm achieving target challenges_d.lobna
ueda2013 t2-dm achieving target challenges_d.lobnaueda2015
 
MedReg+1 Tremble Diabetes
MedReg+1 Tremble DiabetesMedReg+1 Tremble Diabetes
MedReg+1 Tremble DiabetesMedReg+1
 
How To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptxHow To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptxNanangMiftah
 
Management Of Diabetes
Management Of DiabetesManagement Of Diabetes
Management Of Diabetesdoctorshazly
 
Case studies in the managment of type 2 diabetes
Case studies in the managment of type 2 diabetes Case studies in the managment of type 2 diabetes
Case studies in the managment of type 2 diabetes NasserAljuhani
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetesraj kumar
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetesraj kumar
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetesrkrajreliance9
 

Semelhante a Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda (20)

Incretins based therapy :How Early
Incretins based therapy :How EarlyIncretins based therapy :How Early
Incretins based therapy :How Early
 
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise -  khaled el hadidyUeda2016 symposium -managing t2 dm with no compromise -  khaled el hadidy
Ueda2016 symposium -managing t2 dm with no compromise - khaled el hadidy
 
Ranjna.ppt
Ranjna.pptRanjna.ppt
Ranjna.ppt
 
Diabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptxDiabetes Management by Insulin.pptx
Diabetes Management by Insulin.pptx
 
ueda2013 t2-dm achieving target challenges_d.lobna
ueda2013 t2-dm achieving target challenges_d.lobnaueda2013 t2-dm achieving target challenges_d.lobna
ueda2013 t2-dm achieving target challenges_d.lobna
 
MedReg+1 Tremble Diabetes
MedReg+1 Tremble DiabetesMedReg+1 Tremble Diabetes
MedReg+1 Tremble Diabetes
 
Diabetes and insulin
Diabetes and insulinDiabetes and insulin
Diabetes and insulin
 
Starting Insulin by M Daoud
Starting Insulin by M DaoudStarting Insulin by M Daoud
Starting Insulin by M Daoud
 
Diabetes
DiabetesDiabetes
Diabetes
 
How To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptxHow To Change Treatment from OAD to Insulin in Type 2 DM .pptx
How To Change Treatment from OAD to Insulin in Type 2 DM .pptx
 
Management Of Diabetes
Management Of DiabetesManagement Of Diabetes
Management Of Diabetes
 
Insulin: what is new ?
Insulin: what is new ?Insulin: what is new ?
Insulin: what is new ?
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Case studies in the managment of type 2 diabetes
Case studies in the managment of type 2 diabetes Case studies in the managment of type 2 diabetes
Case studies in the managment of type 2 diabetes
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Linagliptin
LinagliptinLinagliptin
Linagliptin
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetes
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetes
 
Drug therapy in diabetes
Drug therapy in diabetesDrug therapy in diabetes
Drug therapy in diabetes
 
DIABETES.pptx
DIABETES.pptxDIABETES.pptx
DIABETES.pptx
 

Último

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 

Último (20)

How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 

Insulinoterapia, Nuevos Retos - Dra. Jenny Cepeda

  • 1. {
  • 2. Banting, Best, Collip y MacLeod 1921 Islotina Mc-Collip Leonard Thompson 11 enero 1922 1936 Hagedorn 1946 NPH Scott y Fisher zinc
  • 3. Entrada glucosa Inhibe producción hepática glucosa Inhibe lipólisis, proteólisis Promueve síntesis proteica Conversión del exceso glucosa a grasa
  • 4. Insulinas porcinas y bovinas Insulina humana Análogos de insulina Insulina inhalada
  • 10. Insulina rápida humana Velocidad de absorción baja Inicia 15 a 60 mins tras inyección Pico 2 a 4 horas. Acción máx.: 5-8 hrs
  • 11. I. Prandiales: Lispro L p Inicia 15 mins EM: 60-90 mins Actua 4-5 hrs Flexible
  • 14. INSULINA INHALADA: 1. Insulina de acción rápida 2. No pctes con asma, broncoespasmos, EPOC o cualquier otra enfermedad pulmonar crónica •No en CAD
  • 15. Insulinas basales: NPH Inicia 2.5- 3 hrs Pico 5-7 hrs Duración 13-16 hrs Reducción basal
  • 18. • Degludec • U300 glargina (Toujeo) • Peglispro INSULINAS MODERNAS http://www.medscape.com/viewarticle/
  • 19. Insulinas precombinadas NPL 75/25 NPA 70/30 Insulina 70/30 Problemas autocombinación Ancianos Trastorno motricidad fina y/o visuales No fácil ajuste Inadecuadas DM 1
  • 21. Objetivos de insulinoterapia Prevenir y retrasar complicaciones micro y macrovasculares Evitar CAD Detener catabolia y recuperar masa magra Reducir infecciones frecuentes Reducir morbimortalidad materno- fetal
  • 22. ADA-EASD Position Statement Update: Management of Hyperglycemia in T2DM, 2015 larga (Detemir) Ultra-rápida (Lispro, Aspártica, Glulisina) Hours Larga (Glargina) 0 2 4 6 8 10 12 14 16 18 20 22 24 Rápida (Regular) Horas después injección Niveldeinsulina (Degludec) TERAPIA ANTI-HIPERGLICEMICA NPH
  • 23. Healthy eating, weight control, increased physical activity & diabetes education Metformin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): Metformin + Metformin + Metformin + Metformin + Metformin + high low risk gain edema, HF, fxs low Thiazolidine- dione intermediate low risk neutral rare high DPP-4 inhibitor highest high risk gain hypoglycemia variable Insulin (basal) Metformin + Metformin + Metformin + Metformin + Metformin + Basal Insulin + Sulfonylurea + TZD DPP-4-i GLP-1-RA Insulin§ or or or or Thiazolidine- dione + SU DPP-4-i GLP-1-RA Insulin§ TZD DPP-4-ior or or GLP-1-RA high low risk loss GI high GLP-1 receptor agonist Sulfonylurea high moderate risk gain hypoglycemia low SGLT2 inhibitor intermediate low risk loss GU, dehydration high SU TZD Insulin§ GLP-1 receptor agonist + SGLT-2 Inhibitor + SU TZD Insulin§ Metformin + Metformin + or or or or SGLT2-i or or or SGLT2-i Mono- therapy Efficacy* Hypo risk Weight Side effects Costs Dual therapy† Efficacy* Hypo risk Weight Side effects Costs Triple therapy or or DPP-4 Inhibitor + SU TZD Insulin§ SGLT2-i or or or SGLT2-i or DPP-4-i If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i: Metformin + Combination injectable therapy‡ GLP-1-RAMealtime Insulin Insulin (basal) + Terapia antihiperglicémica: recomendaciones generales Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 24. Healthy eating, weight control, increased physical activity & diabetes education Metformin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): Metformin + Metformin + Metformin + Metformin + Metformin + high low risk gain edema, HF, fxs low Thiazolidine- dione intermediate low risk neutral rare high DPP-4 inhibitor highest high risk gain hypoglycemia variable Insulin (basal) Metformin + Metformin + Metformin + Metformin + Metformin + Basal Insulin + Sulfonylurea + TZD DPP-4-i GLP-1-RA Insulin§ or or or or Thiazolidine- dione + SU DPP-4-i GLP-1-RA Insulin§ TZD DPP-4-ior or or GLP-1-RA high low risk loss GI high GLP-1 receptor agonist Sulfonylurea high moderate risk gain hypoglycemia low SGLT2 inhibitor intermediate low risk loss GU, dehydration high SU TZD Insulin§ GLP-1 receptor agonist + SGLT-2 Inhibitor + SU TZD Insulin§ Metformin + Metformin + or or or or SGLT2-i or or or SGLT2-i Mono- therapy Efficacy* Hypo risk Weight Side effects Costs Dual therapy† Efficacy* Hypo risk Weight Side effects Costs Triple therapy or or DPP-4 Inhibitor + SU TZD Insulin§ SGLT2-i or or or SGLT2-i or DPP-4-i If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i: Metformin + Combination injectable therapy‡ GLP-1-RAMealtime Insulin Insulin (basal) + Terapia antihiperglicémica: Recomendaciones generales Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 25. Healthy eating, weight control, increased physical activity & diabetes education Metformin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): Metformin + Metformin + Metformin + Metformin + Metformin + high low risk gain edema, HF, fxs low Thiazolidine- dione intermediate low risk neutral rare high DPP-4 inhibitor highest high risk gain hypoglycemia variable Insulin (basal) Metformin + Metformin + Metformin + Metformin + Metformin + Basal Insulin + Sulfonylurea + TZD DPP-4-i GLP-1-RA Insulin§ or or or or Thiazolidine- dione + SU DPP-4-i GLP-1-RA Insulin§ TZD DPP-4-ior or or GLP-1-RA high low risk loss GI high GLP-1 receptor agonist Sulfonylurea high moderate risk gain hypoglycemia low SGLT2 inhibitor intermediate low risk loss GU, dehydration high SU TZD Insulin§ GLP-1 receptor agonist + SGLT-2 Inhibitor + SU TZD Insulin§ Metformin + Metformin + or or or or SGLT2-i or or or SGLT2-i Mono- therapy Efficacy* Hypo risk Weight Side effects Costs Dual therapy† Efficacy* Hypo risk Weight Side effects Costs Triple therapy or or DPP-4 Inhibitor + SU TZD Insulin§ SGLT2-i or or or SGLT2-i or DPP-4-i If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i: Metformin + Combination injectable therapy‡ GLP-1-RAMealtime Insulin Insulin (basal) + Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 26. Healthy eating, weight control, increased physical activity & diabetes education Metformin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): Metformin + Metformin + Metformin + Metformin + Metformin + high low risk gain edema, HF, fxs low Thiazolidine- dione intermediate low risk neutral rare high DPP-4 inhibitor highest high risk gain hypoglycemia variable Insulin (basal) Metformin + Metformin + Metformin + Metformin + Metformin + Basal Insulin + Sulfonylurea + TZD DPP-4-i GLP-1-RA Insulin§ or or or or Thiazolidine- dione + SU DPP-4-i GLP-1-RA Insulin§ TZD DPP-4-ior or or GLP-1-RA high low risk loss GI high GLP-1 receptor agonist Sulfonylurea high moderate risk gain hypoglycemia low SGLT2 inhibitor intermediate low risk loss GU, dehydration high SU TZD Insulin§ GLP-1 receptor agonist + SGLT-2 Inhibitor + SU TZD Insulin§ Metformin + Metformin + or or or or SGLT2-i or or or SGLT2-i Mono- therapy Efficacy* Hypo risk Weight Side effects Costs Dual therapy† Efficacy* Hypo risk Weight Side effects Costs Triple therapy or or DPP-4 Inhibitor + SU TZD Insulin§ SGLT2-i or or or SGLT2-i or DPP-4-i If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i: Metformin + Combination injectable therapy‡ GLP-1-RAMealtime Insulin Insulin (basal) + Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 27. Healthy eating, weight control, increased physical activity & diabetes education Metformin high low risk neutral/loss GI / lactic acidosis low If HbA1c target not achieved after ~3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): Metformin + Metformin + Metformin + Metformin + Metformin + high low risk gain edema, HF, fxs low Thiazolidine- dione intermediate low risk neutral rare high DPP-4 inhibitor highest high risk gain hypoglycemia variable Insulin (basal) Metformin + Metformin + Metformin + Metformin + Metformin + Basal Insulin + Sulfonylurea + TZD DPP-4-i GLP-1-RA Insulin§ or or or or Thiazolidine- dione + SU DPP-4-i GLP-1-RA Insulin§ TZD DPP-4-ior or or GLP-1-RA high low risk loss GI high GLP-1 receptor agonist Sulfonylurea high moderate risk gain hypoglycemia low SGLT2 inhibitor intermediate low risk loss GU, dehydration high SU TZD Insulin§ GLP-1 receptor agonist + SGLT-2 Inhibitor + SU TZD Insulin§ Metformin + Metformin + or or or or SGLT2-i or or or SGLT2-i Mono- therapy Efficacy* Hypo risk Weight Side effects Costs Dual therapy† Efficacy* Hypo risk Weight Side effects Costs Triple therapy or or DPP-4 Inhibitor + SU TZD Insulin§ SGLT2-i or or or SGLT2-i or DPP-4-i If HbA1c target not achieved after ~3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference - choice dependent on a variety of patient- & disease-specific factors): If HbA1c target not achieved after ~3 months of triple therapy and patient (1) on oral combination, move to injectables, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1-RA or mealtime insulin. In refractory patients consider adding TZD or SGL T2-i: Metformin + Combination injectable therapy‡ GLP-1-RAMealtime Insulin Insulin (basal) + Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442 HbA1c ≥9% Intolerancia o contraindicación metformina Hiperglicemia incontrolada (cuadros catabólicos, Gp ≥300-350 mg/dl, HbA1c ≥10-12%)
  • 29. Inicio DM 1 y DM2 con síntomas Cuadros agudos, hospitalización Diabetes gestacional sin control y pregestacional Insuficiencia renal y hepática Falla terapéutica ADO CON EL TX DE INSULINA EN RECIEN DX SE HA DEMOSTRADO UN AUMENTO DE LA SECRESION DE LA MISMA TANTO 1ERA COMO 2DA FASE ORIGIN A DOSIS 0.1 A 0.15 U DE ANALOGOS REDUCIENDO 30-35 % DE LA PROGRESION DE DIABETES
  • 30. • Edad/expectativa de vida • Comorbilidades • Duración de la diabetes • Hipoglicemias • Consideraciones individuales • Enf. Cardiovasculares/ complicaciones microvasculares avanzadas
  • 31. more stringent less stringent Patient attitude and expected treatment efforts highly motivated, adherent, excellent self-care capacities less motivated, non-adherent, poor self-care capacities Risks potentially associated with hypoglycemia and other drug adverse effects low high Disease duration newly diagnosed long-standing Life expectancy long short Important comorbidities absent severefew / mild Established vascular complications absent severefew / mild Readily available limited Usually not modifiable Potentially modifiable HbA1c 7% PATIENT / DISEASE FEATURES Approach to the management of hyperglycemia Resources and support system Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 33. Add ≥2 rapid insulin* injections before meals ('basal-bolus’† ) Change to premixed insulin* twice daily Add 1 rapid insulin* injections before largest meal • Start: Divide current basal dose into 2/3 AM, 1/3 PM or 1/2 AM, 1/2 PM. • Adjust: é dose by 1-2 U or 10-15% once- twice weekly until SMBG target reached. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. • Start: 10U/day or 0.1-0.2 U/kg/day • Adjust: 10-15% or 2-4 U once-twice weekly to reach FBG target. • For hypo: Determine & address cause; ê dose by 4 units or 10-20%. Basal Insulin (usually with metformin +/- other non-insulin agent) If not controlled after FBG target is reached (or if dose > 0.5 U/kg/day), treat PPG excursions with meal-time insulin. (Consider initial GLP-1-RA trial.) If not controlled, consider basal- bolus. If not controlled, consider basal- bolus. • Start: 4U, 0.1 U/kg, or 10% basal dose. If A1c<8%, consider ê basal by same amount. • Adjust: é dose by 1-2 U or 10-15% once- twice weekly until SMBG target reached. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. • Start: 4U, 0.1 U/kg, or 10% basal dose/meal.‡ If A1c<8%, consider ê basal by same amount. • Adjust: é dose by 1-2 U or 10-15% once-twice weekly to achieve SMBG target. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. Enfoque para inicio y ajuste de tx insulínico Dm 2 Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 34. Add ≥2 rapid insulin* injections before meals ('basal-bolus’† ) Change to premixed insulin* twice daily Add 1 rapid insulin* injections before largest meal • Start: Divide current basal dose into 2/3 AM, 1/3 PM or 1/2 AM, 1/2 PM. • Adjust: é dose by 1-2 U or 10-15% once- twice weekly until SMBG target reached. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. • Start: 10U/day or 0.1-0.2 U/kg/day • Adjust: 10-15% or 2-4 U once-twice weekly to reach FBG target. • For hypo: Determine & address cause; ê dose by 4 units or 10-20%. Basal Insulin (usually with metformin +/- other non-insulin agent) If not controlled after FBG target is reached (or if dose > 0.5 U/kg/day), treat PPG excursions with meal-time insulin. (Consider initial GLP-1-RA trial.) low mod. high more flexible less flexible Complexity # Injections Flexibility 1 2 3+ If not controlled, consider basal- bolus. If not controlled, consider basal- bolus. • Start: 4U, 0.1 U/kg, or 10% basal dose. If A1c<8%, consider ê basal by same amount. • Adjust: é dose by 1-2 U or 10-15% once- twice weekly until SMBG target reached. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. • Start: 4U, 0.1 U/kg, or 10% basal dose/meal.‡ If A1c<8%, consider ê basal by same amount. • Adjust: é dose by 1-2 U or 10-15% once-twice weekly to achieve SMBG target. • For hypo: Determine and address cause; ê corresponding dose by 2-4 U or 10-20%. Enfoque para inicio y ajuste de tx insulinico Dm2 Diabetes Care 2015;38:140-149; Diabetologia 2015;58:429-442
  • 35. 0.2 a 0.5 U/ kg: 50% basal (2/3 y 1/3) 50% bolus Conteo CBH: 1 U <> 15 g CBH Automonitoreo DM 1
  • 36. Síntomas de hiperglicemia Contraindicación ADO HbA1c >9 % Cuadros agudos GA >250 mg/dl y GPP > 350 mg/dl Embarazo DM 2
  • 38. { CenaAlmuerzoDesayuno 5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am 3am 4am Horarios y tiempos de comida
  • 39. { CenaAlmuerzoDesayuno 5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am 3am 4am Horarios y tiempos de comida
  • 40. { CenaAlmuerzoDesayuno 5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am 3am 4am Horarios y tiempos de comida
  • 41. { CenaAlmuerzoDesayuno 5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am 3am 4am Horarios y tiempos de comida
  • 42. { CenaAlmuerzoDesayuno 5am 6am 7am 8am 9 am 10am 11am 12md 1 pm 2pm 3pm 4pm 5pm 6pm 7pm 8pm 9pm 10pm 11pm 12pm 1am 2am 3am 4am Horarios y tiempos de comida

Notas do Editor

  1. EFICACIA BIOLOGICA. 1921 universidad toronto Islotina por banting y best para luego llamarse insulina por macleod y adecuadamente collip (bioqco) Hospital gnral toronto Protamina de pescado. Insulina protamina cinc
  2. SECUENCIA PROTEINICA COMPLETA. SANGER 1958 ZONAS DE INVARIABILIDAD EN AAS DE CISTEINA, CONFIEREN LA ADECUACION AL RECEPTOR DE INSULINAZ
  3. 1.1EROS 60 AÑOS 2.DECENIO DE LOS 80 3. ANOS 90 4. JUNIO 2014 SANOFI AVENTIS
  4. UKPDS 5,102 DM2 10 AÑOS. REDUCCION DE 1% A1C HAY REDUCCION 14% PARA EL IAM, 12% ICTUS, 43% PARA AMPUTACION
  5. DIGAMI. TX INTENSIVO CON INSULINA TRAS UN IAM REDUCE MORTALIDAD Y EL USO DE BOMBA DE INFUSION C INSULINA MAS GLUCOSA REDUJO MORTALIDAD INTRAHOSP 58% Y LA MORTALIDAD GLOBAL A 1 AÑO 52 % DCCT RETINOPATIA 76%, NEUROPATIA 69%, NEFROPATIA 34%
  6. VER PAG 117 DE GARCIA DR
  7. NO SIMULA LA SECRESION FISIOL DE INSUL POR LO TANTO DEBE DARSE 30 A 45 MINS ANTES D LA COMIDA PARA Q COINCIDA CON LA ABSORCION DE LOS HC
  8. LISPRO RECORDAR Q LA INSULINA SE AUTOAGREGA EN HEXAMEROS….. PAG 660 JOSLIN ESTO REDUCE LA AUTOAGREGACION FLEXIBLE: MENOS HIPOG, CONTEO CBH , COLOCAR C/COMIDAS Preferidas para la bomba de infusion HIUMALOG
  9. ASPARTATO EN LUGAR DE PROLINA POSICION B28. REPULSION DE LAS CARGAS POR EL ACIDO (CARGA NEGATIVA), POR LO TANTO HAY REPULSION Con esta y la lispro: menor hipoglicemia nocturna ==NOVORAPID
  10. Apidra SUSTITUCION DE ASPARAGINA EN B3 POR LISINA Y EN B29 SUSTITUIR LISINA POR AC GLUTAMICO UNICA Q NO TIENE ZINC
  11. AFREZZA Hacer espirometría APROBADA 27 DE JUNIO 2014
  12. HABLAR DE LA PRESENTACION U-100 Y U-500
  13. SE ELIMINA EL B30 TREONINA Y SE ACIDIFICA LA CADENA LAT B, ANADIENDO ACIDO TETRADECANOICO(ac miristico) AL B29 (ac graso alifatico). UNION REVERSIBLE C/ALBUMINA Y EL AC GRASO ACILADO A LA INSULINA
  14. SE AGREGA 2 AAS ARGININA. ESTO DESPLAZA EL PUNTO ISOELECTRICO DE LA PROT DE UN PH DE 5.4 A UN PH 6.7. ESTO MOTIVA Q LA MOLECULA SEA MAS SOLUBLE EN UN PH ACIDO Y MENOS SOLUBLE A UN PH NEUTRO. ERA NEC UNA SEGUNDA SUST PARA EVITA LA DESAMIDACION NO DESEADA DE LA ASPARAGINA A21 Q TIENE LUGAR A PH BAJOS. LA SUST DE ASN A21 POR GLICINA EVITA ESTE PROBLEMA VARIABILIDAD INTRAINDIVIDUAL
  15. 1. TRESIBA (NOVO) APROBADA POR LA UNIN EUROPEA DESDE JUNIO 2013, NO POR FDA. SE DA EN CUALQ MTO DEL DIA 2. Aprobada Miercoles 25 de feb (sanofi) TIENE LA CONCENTRACION DE 3 VECES DE LA GLARGINA, ES LA LIBERACION MAS GRADUAL DE LA INSULINA Y ES LLAMADA INSULINA DE ACCION ULTRALARGA. 3. TB DE ACCION ULTR LARGA LILY
  16. Ver pag 661 para detalles de insulinas (joslin) HUMALOG MIX
  17. Here is a diagrammatic representation of the approximate pharmacokinetic properties of various insulin formulations. Understanding the onset, peak and duration of action of insulin products is key for successful management of patients with diabetes.
  18. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, the usual transition being vertical, from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). The figure denotes relative glucose lowering efficacy, risk of hypoglycemia, effect on body weight, other side effects and approximate relative cost for each drug class. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis, unless there are contraindications.
  19. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, the usual transition being vertical, from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). The figure denotes relative glucose lowering efficacy, risk of hypoglycemia, effect on body weight, other side effects and approximate relative cost for each drug class. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis, unless there are contraindications.
  20. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, the usual transition being vertical, from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). The figure denotes relative glucose lowering efficacy, risk of hypoglycemia, effect on body weight, other side effects and approximate relative cost for each drug class. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis, unless there are contraindications.
  21. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, the usual transition being vertical, from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). The figure denotes relative glucose lowering efficacy, risk of hypoglycemia, effect on body weight, other side effects and approximate relative cost for each drug class. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis, unless there are contraindications.
  22. Potential sequences of antihyperglycemic therapy for patients with type 2 diabetes are displayed, the usual transition being vertical, from top to bottom (although horizontal movement within therapy stages is also possible, depending on the circumstances). The figure denotes relative glucose lowering efficacy, risk of hypoglycemia, effect on body weight, other side effects and approximate relative cost for each drug class. In most patients, begin with lifestyle changes; metformin monotherapy is added at, or soon after, diagnosis, unless there are contraindications.
  23. RECODAR GA MAYOR 250, AL AZAR MAYOR DE 300, A1C MAYOR 9 %
  24. This slide shows glycemic targets for nonpregnant adults with diabetes from the 2015 ADA guidelines. Refer to source document for full recommendations, including level of evidence rating. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93. January 2014 This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.
  25. This is a depiction of the elements of decision-making used to determine the intensivenss of efforts to achieve glycemic targets. Greater concerns about a particular domain are represented by increasing height of the ramp. Thus, characteristics/predicaments towards the left justify more stringent efforts to lower HbA1c, whereas those towards the right are compatible with less stringent efforts. In general, most patients should be targeted to <7%, but as previously discussed, tighter targets may benefit younger patients whereas in older individuals, a more conservative approach is necessary. Where possible, such decisions should be made in conjunction with the patient, reflecting his or her preferences, needs and values. This ‘scale’ is not designed to be applied rigidly but to be used as a broad construct to help guide clinical decisions. (Adapted with permission from Ismail-Beigi et al, Ann Intern Med 2011;154:554-559.)
  26. Basal insulin alone is usually the optimal initial regimen, beginning at 0.1-0.2 U/kg body weight, depending on the degree of hyperglycemia. It is usually prescribed in conjunction with 1-2 non-insulin agents, although insulin secretagogues (sulfonylureas, meglitinides) are typically stopped once more complex regimens beyond basal insulin are utilized. In patients still not at target after basal insulin has been adequately titrated, and the patient is willing to take >1 injections, there are several options. First, consider GLP-1 receptor agonists (see Fig. 2). The combination of basal insulin + GLP-1RA is becoming well established after several studies confirmed its efficacy on par with more complex multi-dose insulin regimens, but with less hypoglycemia and with weight loss instead of weight gain. If such an approach is not possible or has been tried and proven unsuccessful, there are 3 possible advanced insulin regimens: Adding 1 injection of a rapid acting insulin analogue before the largest meal, Adding 2-3 injections of a rapid acting insulin analogue before 2-3 meals, or Using premixed insulin BID Each approach has its advantages and disadvantages. The figure describes the number of injections required at each stage, together with the relative complexity and flexibility. A fourth, less common method (not shown) is referred to as ‘self-mixed split’ and involves 2 injections of NPH mixed with regular human insulin (or mixed with a rapid acting insulin analogue), administered before breakfast and the evening meal. This is a more cost-effective approach, using human insulins in vials, and allows self-adjustment by the patient of the short/rapid-acting component, based on pre-meal blood glucose or anticipated carbohydrate intake (or both.)   Once a strategy is initiated, titration of the insulin dose is important, with dose adjustments made based on the prevailing BG levels as reported by the patient. Comprehensive education regarding self-monitoring of BG, diet, exercise, and the avoidance of, and response to, hypoglycemia are critical in any patient on insulin therapy.
  27. Basal insulin alone is usually the optimal initial regimen, beginning at 0.1-0.2 U/kg body weight, depending on the degree of hyperglycemia. It is usually prescribed in conjunction with 1-2 non-insulin agents, although insulin secretagogues (sulfonylureas, meglitinides) are typically stopped once more complex regimens beyond basal insulin are utilized. In patients still not at target after basal insulin has been adequately titrated, and the patient is willing to take >1 injections, there are several options. First, consider GLP-1 receptor agonists (see Fig. 2). The combination of basal insulin + GLP-1RA is becoming well established after several studies confirmed its efficacy on par with more complex multi-dose insulin regimens, but with less hypoglycemia and with weight loss instead of weight gain. If such an approach is not possible or has been tried and proven unsuccessful, there are 3 possible advanced insulin regimens: Adding 1 injection of a rapid acting insulin analogue before the largest meal, Adding 2-3 injections of a rapid acting insulin analogue before 2-3 meals, or Using premixed insulin BID Each approach has its advantages and disadvantages. The figure describes the number of injections required at each stage, together with the relative complexity and flexibility. A fourth, less common method (not shown) is referred to as ‘self-mixed split’ and involves 2 injections of NPH mixed with regular human insulin (or mixed with a rapid acting insulin analogue), administered before breakfast and the evening meal. This is a more cost-effective approach, using human insulins in vials, and allows self-adjustment by the patient of the short/rapid-acting component, based on pre-meal blood glucose or anticipated carbohydrate intake (or both.)   Once a strategy is initiated, titration of the insulin dose is important, with dose adjustments made based on the prevailing BG levels as reported by the patient. Comprehensive education regarding self-monitoring of BG, diet, exercise, and the avoidance of, and response to, hypoglycemia are critical in any patient on insulin therapy.
  28. ESPERAR AL MENOS 3 DIAS PARA LOS CAMBIOS ( ESPERAR ESTABILIZACION DEL ANALOGO)
  29. Insuf hepatica, renal, o cardiaca severa RECORDAR EL SLIDING SCALE DEL JOSLIN ( 1934) QUE SE USA EN PCTES HOSP, AGUDOS, PREQX NO SEGURO DE SU TX, HOSP EN GRAL, ETC. PARA PASAR DE ESTA FORMA DE TX A OTRA ( COMO BASAL/BOLUS) DEBEMOS REDUCIR 20 % DE LA DOSIS TOTAL A MENOS Q SEA DETEMIR
  30. This slide reviews recommended pharmacologic therapy for treating and managing type 2 diabetes from the 2015 ADA guidelines PREFERENCIA DEL PCTE. USO DE INSULINA EN EL DM2 DE INICIO RECIENTE YA QUE ES UNO DE LAS POCAS TX CON BENEFICIO DOCUMENTADO EN REDUCCION DE COMPLICACIONES A LARGO PLAZO. TB COMO METODO EFECTIVO PARA PRESERVACION DE LA FUNCION DE CELS BETA QUE ESTA ASOC A MEJOR CONTROL GLICEMICO A LARGO PLAZO. ADA PAG 473 Refer to source document for full recommendations, including level of evidence rating. American Diabetes Association. Standards of medical care in diabetes—2015. Diabetes Care. 2015;38(suppl 1):S1-S93. January 2014 Any pharmacologic agents discussed are approved for use in the United States by the U.S. Food and Drug Administration (FDA) unless otherwise noted. Consult individual prescribing information for approved uses outside of the United States. This slide was created by Ashfield Healthcare Communications and was not associated with funding via an educational grant or a promotional/commercial interest.
  31. ESTUDIO TREAT TO TARGET AGREGAR INSULINA BASAL A ADO CON A1C PROMEDIO 8.6% ALCANZARON AIC EL 60 % EN 24 SEMS ( UN GRUPO CON ANALOGOS, OTRO CON INSULINA) GRALMT AL INICIAR INSULINOTX
  32. AUMENTAR DE 10 AL 20% HASTA ALCANZAR META
  33. SE DEBE ELIMNAR LOS SECRETAGOGOS CON LOS BOLOS PRANDIALES PORQ SE SINERGIZA LAS HIPOGLICEMIAS, SE DEBEN DEJAR LOS INSULINOSENSIBILIZADORES YA Q LA INSULINORESISTENCIA PERSISTE MEJORA GLICEMIA POSTINGESTA REQUIERE MERIENDA 4HRS DESP DE INYECCION PARA EVITAR HIPOG TARDIAS
  34. RECORDAR ROTAR, TEMPERATURA Y MASAJE NPH 20-50% SE DEGRADA LOCALMENTE DETEMIR TIENE MENOR VARIABILIDAD INTRAINDIVIDUAL TB MEDICAMENTOS Y PATOLOGIAS ENDORINOL
  35. 2. Efecto anabolico 4. ATROFICA E HIPERTROFICA 3. AUMENTO DEL SODIO NEUROPATIA INSULINICA 6. DISMINUCION TRANSITORIA DE LA AGUDEZA VISUAL POR HIDRATAX DEL CRISTALINO